Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine is a vaccine comprising purified SARS-CoV-2 spike protein expressed in plant-based virus-like particles for the prevention of COVID-19 in adult patients. It is composed of VLPs expressing SARS-CoV-2 spike protein trimers (stabilized in a pre-fusion conformation) and is mixed with the AS03 adjuvant system prior to administration.
- Mechanism
- Curator reviewed · 4 references
Covifenz is a recombinant and adjuvanted vaccine produced by plant-based technology. The antigenic portion of the vaccine is produced by delivering the SARS-CoV-2 spike protein genomic sequence into host leaf cells of non-transgenic plants utilizing a bacterial vector. The newly transgenic plant then serves as a bioreactor for producing virus-like particles (VLPs), which are self-assembled structures that resemble viruses but are absent viral genetic material and therefore non-infectious. The enveloped VLPs present spike protein trimers stabilized in a pre-fusion conformation on their surface which, following intramuscular administration, elicit both neutralizing antibody and cellular immune responses to SARS-CoV-2 spike proteins.
Covifenz also contains an adjuvant, AS03, which is mixed with the antigenic component prior to administration to enhance the immune response to the vaccine.
- Primary indication
- The Covifenz COVID-19 vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in patients 18 years of age and older.Curator reviewed · 1 structured indication
- Also known as
- Covifenz
What you can answer from here — as of August 01, 2025
Which other approved drugs treat the same conditions as Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account